Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
Holders of 5% or more of ITCI
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Intra-Cellular Therapies, Inc., largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Intra-Cellular Therapies, Inc. on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
2 Schedule 13D and 13G filings on Intra-Cellular Therapies, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 5, 20251:42 PM ET | JPMorgan Chase & Co | 13G/A | 0.00%0 shares | –Below 5% | May 30, 2025 | SEC |
| Feb 7, 202510:23 AM ET | FMR LLCand 1 other | 13G/A | 2.50%2.70M shares | –Below 5% | Jan 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Intra-Cellular Therapies, Inc. shares.
No Form 144 notices for Intra-Cellular Therapies, Inc. are on file.